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Molecular genetics of MODY in Germany
Dear Sir, Ledermann has suggested that approximately 2 % of all diabetic patients in Germany are likely to have maturity-onset diabetes of the young (MODY) [1] . The contribution of mutations in the known MODY genes to the overall prevalence of this form of diabetes in Germany is not known. As a first step in addressing this problem, we have studied 11 families of German ancestry with a probable diagnosis of MODY, i. e. diagnosis of diabetes before 25 years of age in at least one family member and other first-degree relatives with MODY or Type II (non-insulin-dependent) diabetes ( Fig. 1 ). Family Dresden-1 was from the state of North Rhine-Westfalia, families Dresden-2, ±4, ±6, ±7, ±13, ±15, and ±17 from Saxony, and families Dresden-3, ±5, and ±11 were from Thuringia. The average age at diagnosis of diabetes in the probands was 18.2 ± 6.6 (range 12±25 years) (means ± SEM) and included four men and seven women. Of the eleven probands, six, two and three were currently being treated with insulin, oral hypoglycaemic agents and diet, respectively. The average body mass index (BMI) was 25.7 ± 5.9 kg/m 2 (range Letters 121 (1) Insulin requiring when symptomatic on maximum sulphonylurea and metformin therapies (2) Allocated to chlorpropamide as fasting glucose > 6.0 mmol/l (3) Allocated to diet and transferred to sulphonylurea therapy when fasting glucose > 15 mmol/l 19.3±39.5). At the time of recruitment informed consent was obtained from each subject and blood and urine samples were obtained for DNA isolation and clinical testing. The promoter, coding and flanking intron regions of the hepatocyte nuclear factor HNF-1a, HNF-1b and HNF-4a genes were screened for mutations as were the coding and flanking intron regions of the glucokinase and insulin promoter factor (IPF)-1 genes by direct sequencing of polymerase chain reaction (PCR) products [2] . Since glucokinase mutations are associated with a mild increase in fasting and postprandial blood glucose concentrations or impaired glucose tolerance usually treated with diet, we only screened families with mild diabetes for mutations in this gene (i. e. Dresden-6, ±7, and ±13).
Mutations associated with diabetes were identified in six families. We found four families with mutations in the HNF1a gene (Dresden-1, P291fsinsC; Dresden-2, R131Q; Dresden-3, R229Q; and Dresden-17, R272fsdelGC), one had a mutation in the HNF-4a gene (Dresden-11, R154X) and one had a novel frameshift mutation in the glucokinase gene (Dresden-7) (V154fsdelTG). All of these mutations co-segregated with diabetes suggesting that they play a causal role in its development (Fig. 1) . No mutations were found in the HNF-1b or IPF-1 genes in families Dresden-4, ±5, ±6, ±7, ±13, ±15, ±17 (the probands of Dresden-1, ±2, ±3 and ±11 were not screened for mutations in these genes because they had mutations in other MODY genes). A variety of previously described silent mutations and polymorphisms were observed in the HNF-1a, -1b and -4a genes in a number of subjects as were several novel nucleotide substitutions including a silent mutation in the codon for Ala392 (exon 2) (N392, AAC®AAT) of the HNF-4a gene and a T®C transition in intron 6 of the HNF-1b gene (IVS6nt + 27T®C). No mutations in the HNF-1a and -4a genes were found in families Dresden-4, ±5, ±6, ±7 ±13, ±15. The genetic basis of MODY in these families is not known. We cannot exclude glucokinase mutations in families Dresden-4, ±5, and ±15 since we did not screen families with severe diabetes for mutations in this gene. These MODYx families could be useful in mapping and identifying other MODY genes. There was no evident difference in phenotype between these MODYx probands compared with those with mutations in the HNF-1a and -4a genes.
This study indicates that mutations in the HNF-1a, HNF4a and glucokinase genes are the cause of diabetes in 55 % of our MODY families: HNF-1a, 36 % (4/11); HNF-4a, 9 % (1/ 11); glucokinase, 8 % (1/11). We found no mutations in the HNF-1b and IPF-1 genes. The trend of these results is similar to those of a study of molecular genetics of MODY in the United Kingdom that reported mutations in HNF-1a in 65 % (36/ 55) of MODY families, glucokinase in 11 % (8/55), HNF-4a in 4 % (2/55) and no mutations in HNF-1b or IPF-1 [3] . Another study of MODY in France found glucokinase mutations to be the most common cause of MODY, accounting for 63 % (42/67) of cases and HNF-1a mutations being responsible for 21 % (14/67) with no mutations in HNF-1b, HNF-4a and IPF-1 [4] . These contrasting results could be caused by the different types of patients studied; adult diabetic patients in the German and United Kingdom study, whereas in France most patients were referred by paediatric clinics [3] . The failure to find mutations in known MODY genes in all three studies implies that there are unknown MODY genes. The variable clinical phenotype of our so-called MODYx families suggests that there could be at least two unknown loci with one responsible for the mild form of diabetes seen in Dresden-13 and the other for the more severe and often insulin requiring form of MODY seen in Dresden-5, ±6 and ±15.
Ledermann has suggested that 2 % (60 000 patients) of all diabetic patients in Germany have MODY [1, 5] . Our results suggest that 22 800 patients have mutations in the HNF-1a gene and 4800 each could have mutations in the HNF-4a and glucokinase genes. These patients and their families would benefit from genetic counselling since prompt diagnosis and treatment can reduce the complications of HNF-1a and HNF4b diabetes. 
